Ditch
Two things
First with control of the Company they could spin out the cancer drug into a separate Company along with Stiffymist and then a variety of other possibilities
Or
They could hang around for the royalties and then on sell the whole lot at a large profit. Suda is a Company that has a massive back end forming due to the nature of our business being value adding to existing drugs (lots and lots of them) rather than a new drug to market (single drug)
The rule book on PE investment is not relevant to Suda.
This is one unique opportunity and it is up to the encumbent management to succeed.
Suda does need however to sort its Board quickly and I know it is very high on their Corporate agenda as we need some diversity and a new Chairman to drive this Company.
Clyde
